A bone-anchored hearing device (BAHD) is currently the de facto treatment for single-sided deafness (SSD). However, there exists no established evidence-based protocol for fitting/prescribing amplification for this population. In this study, participants will undergo objective and subjective outcomes measures under different fitting rationales to measure and report differences. No existing studies have researched or compared the manufacturer’s settings to an established prescription (DSL) for the SSD population.
SAC would like to thank BMS Canada for their generous sponsorship and support of clinical research in Canada.